Monobactams

Monobactams is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:

-- The first section of this topic is shown below --

General Principles

  • Aztreonam (1–2 g IV/IM q6–12h) is a monobactam that is active only against aerobic gram-negative bacteria, including P. aeruginosa.
  • It is useful in patients with known serious β-lactam allergy because there is no apparent cross-reactivity.
  • Aztreonam is also available in an inhalational dosage form (75 mg inhaled q8h for 28 days) to improve respiratory symptoms in cystic fibrosis patients infected with 
P. aeruginosa.

-- To view the remaining sections of this topic, please or --

General Principles

  • Aztreonam (1–2 g IV/IM q6–12h) is a monobactam that is active only against aerobic gram-negative bacteria, including P. aeruginosa.
  • It is useful in patients with known serious β-lactam allergy because there is no apparent cross-reactivity.
  • Aztreonam is also available in an inhalational dosage form (75 mg inhaled q8h for 28 days) to improve respiratory symptoms in cystic fibrosis patients infected with 
P. aeruginosa.

There's more to see -- the rest of this entry is available only to subscribers.